Immunoreactive androgen receptor expression in subjects with androgen resistance

Carol M. Wilson, Jim Griffin III, Jean D. Wilson, Marco Marcelli, Sonia Zoppi, Michael J. Mcphaul

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Individuals with androgen resistance encompass a spectrum of phenotypic abnormalities ranging from complete testicular feminization to undervirilized men. Such subjects have been classified according to the hormone-binding characteristics in genital skin fibroblasts and on the basis of the mutation in the androgen receptor (AR) gene. Antibodies to the amino-terminal region of the human AR were used to develop an immunoblot assay for the comparison of androgen binding with the amount of AR expressed in genital skin fibroblasts. In controls and 4 androgen-resistant subjects with DNA-binding domain mutations, levels of immunoreactive AR correlated closely with androgen-binding capacity. In 15 androgen-resistant subjects with qualitatively abnormal AR, immunoreactive AR levels tended to be higher than predicted from the ligand-binding capacity. Discordance between immunoreactivity and androgen binding also occurred in fibroblasts from 3 other subjects. One carries a stop codon in the AR gene and produces a truncated AR that is immunoreactive but does not bind androgen. Two carry single point mutations in the hormone-binding domain and produce immunoreactive AR that is normal in size but does not bind androgen.

Original languageEnglish (US)
Pages (from-to)1474-1478
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume75
Issue number6
StatePublished - Dec 1992

Fingerprint

Androgen Receptors
Androgens
Fibroblasts
Skin
Genes
Hormones
Androgen-Insensitivity Syndrome
Mutation
Terminator Codon
Point Mutation
Assays
Ligands
Antibodies
DNA

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Wilson, C. M., Griffin III, J., Wilson, J. D., Marcelli, M., Zoppi, S., & Mcphaul, M. J. (1992). Immunoreactive androgen receptor expression in subjects with androgen resistance. Journal of Clinical Endocrinology and Metabolism, 75(6), 1474-1478.

Immunoreactive androgen receptor expression in subjects with androgen resistance. / Wilson, Carol M.; Griffin III, Jim; Wilson, Jean D.; Marcelli, Marco; Zoppi, Sonia; Mcphaul, Michael J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 75, No. 6, 12.1992, p. 1474-1478.

Research output: Contribution to journalArticle

Wilson, CM, Griffin III, J, Wilson, JD, Marcelli, M, Zoppi, S & Mcphaul, MJ 1992, 'Immunoreactive androgen receptor expression in subjects with androgen resistance', Journal of Clinical Endocrinology and Metabolism, vol. 75, no. 6, pp. 1474-1478.
Wilson, Carol M. ; Griffin III, Jim ; Wilson, Jean D. ; Marcelli, Marco ; Zoppi, Sonia ; Mcphaul, Michael J. / Immunoreactive androgen receptor expression in subjects with androgen resistance. In: Journal of Clinical Endocrinology and Metabolism. 1992 ; Vol. 75, No. 6. pp. 1474-1478.
@article{aae1f53a4b5346e6baa302125ae01766,
title = "Immunoreactive androgen receptor expression in subjects with androgen resistance",
abstract = "Individuals with androgen resistance encompass a spectrum of phenotypic abnormalities ranging from complete testicular feminization to undervirilized men. Such subjects have been classified according to the hormone-binding characteristics in genital skin fibroblasts and on the basis of the mutation in the androgen receptor (AR) gene. Antibodies to the amino-terminal region of the human AR were used to develop an immunoblot assay for the comparison of androgen binding with the amount of AR expressed in genital skin fibroblasts. In controls and 4 androgen-resistant subjects with DNA-binding domain mutations, levels of immunoreactive AR correlated closely with androgen-binding capacity. In 15 androgen-resistant subjects with qualitatively abnormal AR, immunoreactive AR levels tended to be higher than predicted from the ligand-binding capacity. Discordance between immunoreactivity and androgen binding also occurred in fibroblasts from 3 other subjects. One carries a stop codon in the AR gene and produces a truncated AR that is immunoreactive but does not bind androgen. Two carry single point mutations in the hormone-binding domain and produce immunoreactive AR that is normal in size but does not bind androgen.",
author = "Wilson, {Carol M.} and {Griffin III}, Jim and Wilson, {Jean D.} and Marco Marcelli and Sonia Zoppi and Mcphaul, {Michael J.}",
year = "1992",
month = "12",
language = "English (US)",
volume = "75",
pages = "1474--1478",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Immunoreactive androgen receptor expression in subjects with androgen resistance

AU - Wilson, Carol M.

AU - Griffin III, Jim

AU - Wilson, Jean D.

AU - Marcelli, Marco

AU - Zoppi, Sonia

AU - Mcphaul, Michael J.

PY - 1992/12

Y1 - 1992/12

N2 - Individuals with androgen resistance encompass a spectrum of phenotypic abnormalities ranging from complete testicular feminization to undervirilized men. Such subjects have been classified according to the hormone-binding characteristics in genital skin fibroblasts and on the basis of the mutation in the androgen receptor (AR) gene. Antibodies to the amino-terminal region of the human AR were used to develop an immunoblot assay for the comparison of androgen binding with the amount of AR expressed in genital skin fibroblasts. In controls and 4 androgen-resistant subjects with DNA-binding domain mutations, levels of immunoreactive AR correlated closely with androgen-binding capacity. In 15 androgen-resistant subjects with qualitatively abnormal AR, immunoreactive AR levels tended to be higher than predicted from the ligand-binding capacity. Discordance between immunoreactivity and androgen binding also occurred in fibroblasts from 3 other subjects. One carries a stop codon in the AR gene and produces a truncated AR that is immunoreactive but does not bind androgen. Two carry single point mutations in the hormone-binding domain and produce immunoreactive AR that is normal in size but does not bind androgen.

AB - Individuals with androgen resistance encompass a spectrum of phenotypic abnormalities ranging from complete testicular feminization to undervirilized men. Such subjects have been classified according to the hormone-binding characteristics in genital skin fibroblasts and on the basis of the mutation in the androgen receptor (AR) gene. Antibodies to the amino-terminal region of the human AR were used to develop an immunoblot assay for the comparison of androgen binding with the amount of AR expressed in genital skin fibroblasts. In controls and 4 androgen-resistant subjects with DNA-binding domain mutations, levels of immunoreactive AR correlated closely with androgen-binding capacity. In 15 androgen-resistant subjects with qualitatively abnormal AR, immunoreactive AR levels tended to be higher than predicted from the ligand-binding capacity. Discordance between immunoreactivity and androgen binding also occurred in fibroblasts from 3 other subjects. One carries a stop codon in the AR gene and produces a truncated AR that is immunoreactive but does not bind androgen. Two carry single point mutations in the hormone-binding domain and produce immunoreactive AR that is normal in size but does not bind androgen.

UR - http://www.scopus.com/inward/record.url?scp=0026740039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026740039&partnerID=8YFLogxK

M3 - Article

C2 - 1464650

AN - SCOPUS:0026740039

VL - 75

SP - 1474

EP - 1478

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -